Investigational drug · Phase 2
CORT113176
Also called: Dazucorilant
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Amyotrophic Lateral Sclerosis.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "CORT113176"
First trial start
2022
Nov 15, 2022
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CORT113176", any sponsor or status.
Conditions studied
As listed on its trial records.
- Amyotrophic Lateral Sclerosis
Approved drugs for the same conditions: ALS (amyotrophic lateral sclerosis) · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "CORT113176" as an intervention, largest first.
- Dazucorilant in Patients With Amyotrophic Lateral SclerosisPivotal-lookingActive, not recruiting
Corcept TherapeuticsIndustry
NCT05407324 · 279 participants (planned) · Start Nov 15, 2022 · Primary completion Oct 2026
Drug: Dazucorilant 300 mg; Dazucorilant 150 mg and 1 more · For: Amyotrophic Lateral Sclerosis
Sites: Phoenix, Arizona; San Francisco, California; Neptune City, New Jersey · 35 sites in all
- Single and Multiple Ascending Dose Study of CORT113176 in Healthy ParticipantsPivotal-lookingCompleted
Corcept TherapeuticsIndustry
NCT04249323 · 110 participants · Start Jan 27, 2020 · Primary completion Oct 15, 2020
Drug: CORT113176 Lipid Capsule Formulation; Placebo matching CORT113176 Lipid Capsule Formulation and 1 more · For: Healthy Adults
Sites: Ruddington, United Kingdom
Corcept TherapeuticsIndustry
NCT06495944 · 21 participants · Start May 31, 2024 · Primary completion Aug 2, 2024
Drug: Dazucorilant; Itraconazole · For: Healthy Adults
Sites: Baltimore, Maryland
Corcept TherapeuticsIndustry
NCT06928779 · 19 participants · Start Oct 8, 2024 · Primary completion Dec 9, 2024
Drug: Dazucorilant · For: Hepatic Impairment
Sites: Rialto, California; Miami, Florida
Corcept TherapeuticsIndustry
NCT04994743 · 16 participants · Start Jul 13, 2021 · Primary completion Sep 30, 2021
Drug: CORT113176; Placebo matching CORT113176 · For: Healthy Adults
Sites: Groningen, Netherlands
Corcept TherapeuticsIndustry
NCT04990310 · 6 participants · Start Aug 18, 2021 · Primary completion Sep 20, 2021
Drug: [14C]-CORT113176 · For: Healthy
Sites: Ruddington, United Kingdom
Newest research
PubMed records naming it or its code names, newest first.
- Neuropathological Effects of Early Maternal Separation are Prevented by CORT113176, A Glucocorticoid Receptor Modulator.
Niño Rodríguez M, Esperante IJ, Garay LI, et al. · Cell Mol Neurobiol 2026
- Advancing Alzheimer's disease pharmacotherapy: efficacy of glucocorticoid modulation with dazucorilant (CORT113176) in preclinical mouse models.
Canet G, Zussy C, Vitalis M, et al. · Br J Pharmacol 2025
- Glucocorticoid receptor antagonist CORT113176 attenuates motor and neuropathological symptoms of Huntington's disease in R6/2 mice.
Gentenaar M, Meulmeester FL, van der Burg XR, et al. · Exp Neurol 2024
- Stress-induced Neuroinflammation of the Spinal Cord is Restrained by Cort113176 (Dazucorilant), A Specific Glucocorticoid Receptor Modulator.
Meyer M, Meijer O, Hunt H, et al. · Mol Neurobiol 2024
- Corticosterone Levels and Glucocorticoid Receptor Gene Expression in High Drinking in the Dark Mice and Their Heterogeneous Stock (HS/NPT) Founder Line.
Savarese AM, Grigsby KB, Jensen BE, et al. · Front Behav Neurosci 2022
- Glucocorticoid Receptor Antagonist Alters Corticosterone and Receptor-sensitive mRNAs in the Hypoxic Neonatal Rat.
Gehrand AL, Phillips J, Welhouse KD, et al. · Endocrinology 2022
Also in development for Amyotrophic Lateral Sclerosis
- MasitinibAB1010Phase 33 trials
AB Science · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis (ALS), Alzheimer Disease
- SPG302TazbentetolPhase 33 trials
Spinogenix · Alzheimer Disease, Schizophrenia, Amyotrophic Lateral Sclerosis
- PridopidinePhase 32 trials
Prilenia · Amyotrophic Lateral Sclerosis, Huntington Disease
- ION363Phase 31 trial
Ionis Pharmaceuticals · Amyotrophic Lateral Sclerosis
- MN-166ibudilastPhase 31 trial
MediciNova · Amyotrophic Lateral Sclerosis
- CNMAu8gold nanocrystalsPhase 22 trials
Clene Nanomedicine · Amyotrophic Lateral Sclerosis, Multiple Sclerosis
- AMT-162Phase 21 trial
UniQure Biopharma B.V. · Amyotrophic Lateral Sclerosis
- AP-101Phase 21 trial
AL-S Pharma · Amyotrophic Lateral Sclerosis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.